Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06423781 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
A Phase 2 study, sponsored by Biohaven Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 233
- Enrollment target
NCT06423781: Completed Phase 2 study, sponsored by Biohaven Therapeutics.
NCT06423781 is a Phase 2 study that has completed, run by Biohaven Therapeutics. The registered enrollment target is 233 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06423781, a Phase 2 study, has completed, sponsored by Biohaven Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 233 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
Primary Outcome
Safety and tolerability of BHV-7000 as assessed by frequency of unique subjects with SAEs; AEs leading to discontinuation; AEs judged to be related to study medication
Interventions
- DRUG BHV-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2026-03-18 |
| Phase | Phase 2 |
What the finished NCT06423781 record still lists
NCT06423781 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% higher).
The record links to 0 conditions, and to 1 intervention - of which BHV-7000 is the first listed.
NCT06423781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06423781 about?
NCT06423781 is a clinical study titled "Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)". The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
What is the current status of trial NCT06423781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2024-08-01. Estimated completion is 2026-03-18.
What interventions are being tested in trial NCT06423781?
The interventions under investigation include: BHV-7000 (DRUG).
Who is sponsoring clinical trial NCT06423781?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06423781's enrollment target sits among peer trials
233 256th of 2000 higher than 1,745 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06993844 · 233 participants · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NCT07141706 · 233 participants · Phase 1
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI